Hearing Loss Trial, Recruiting NCT06945848 Sponsor: University Hospital, Montpellier Condition: Hearing Loss
Back to Hearing Loss

Hearing Loss Trial, Recruiting

NCT06945848
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have a confirmed diagnosis of Idiopathic Intracranial Hypertension (IIH) — a condition where pressure in the skull is too high — that was made using a specific set of medical criteria, and you have been on standard medical treatment including a medicine called acetazolamide for more than 1 year
  • Your intracranial (skull) pressure has been measured and found to be above a certain high level
  • A brain scan (MRI) has shown a narrowing in specific veins inside your skull called the transverse venous sinuses
  • Your MRI results are otherwise normal, apart from findings related to IIH or the vein narrowing mentioned above
  • You have been given information about the trial, and you have signed and dated a consent form agreeing to take part
  • You are able to attend all required appointments and follow all trial procedures
  • You are covered by public health insurance

Who may not be able to join:

  • You have taken a medicine called topiramate in the past month
  • You have a known allergy to contrast dye (used in scans), nickel, or titanium
  • You have taken certain medicines (such as lithium, vitamin A, tetracyclines, or similar drugs) within 2 months of your IIH diagnosis that are known to raise pressure in the skull
  • You have a history of a blood clot in a brain vein (intracranial venous thrombosis) or a brain tumour
  • You have experienced a rapid and severe loss of vision in your worse eye due to IIH, along with significant damage to your visual field
  • You have damage (wasting) of your optic nerve (the nerve connecting your eye to your brain)
  • You have a condition called amblyopia (sometimes called "lazy eye")
  • You have a high level of short- or long-sightedness or astigmatism alongside certain other eye conditions such as glaucoma or other causes of vision loss (confirm with trial site)
  • You are pregnant, or a pregnancy test comes back positive
  • You have a serious or life-threatening illness that would make it unlikely you would benefit from the procedure or be able to complete the trial
  • There is evidence of bleeding inside your skull (such as a brain haemorrhage)
  • Your life expectancy is less than 6 months
  • You have kidney failure or poor kidney function, unless you are already on dialysis
  • You have previously had a stent placed inside a vein in your skull
  • You have previously had gastric bypass surgery
  • You have a medical reason why you cannot have a general anaesthetic
  • You cannot take blood-thinning or anti-clotting medicines such as aspirin, clopidogrel, or similar drugs
  • You have a history of chronic lung disease or another serious breathing condition
  • You have a history of deep vein thrombosis (a blood clot, usually in the leg) or a pulmonary embolism (a blood clot in the lungs)
  • You have a history of an irregular heart rhythm (atrial fibrillation) or other conditions that increase your risk of stroke
  • You have certain blood vessel abnormalities in the brain, such as aneurysms, arteriovenous malformations, or significant narrowing of other blood vessels in or around the brain
  • The shape or structure of your veins in the skull makes it unsafe to carry out the procedure (confirm with trial site)
  • You work for or are otherwise dependent on the organisation running this trial
  • You have taken part in another clinical trial or received an unapproved medicine within the last 4 weeks
  • You are in a legally protected category under French law, such as being under legal guardianship, being a prisoner, or being pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vincent COSTALAT, MD, PhD, University hospital of Montpellier, FRANCE

Phone: +33 467 337 532

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 January 2026
Est. completion
5 January 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Rate of patients with normalization of intra-cranial pressure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov